| Literature DB >> 2803923 |
L Bettan-Renaud1, F de Vathaire, J Bénard, N Morardet, N Pauzie, S Bayet, O Hartmann, C Parmentier.
Abstract
Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and appears to be valid in bone marrow purging.Entities:
Mesh:
Substances:
Year: 1989 PMID: 2803923 PMCID: PMC2247099 DOI: 10.1038/bjc.1989.307
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640